Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
The device is intended for initial treatment in the acute settingSARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc....
Pharmaceutical
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
Kane Also Signs Long-Term Manufacturing Agreement With Halo PharmaWINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-...
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
– Transaction aligns with Coherus’ strategic focus on oncology –REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences,...
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing...
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company...
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Additional $6.7M in funding resulting in approximately $67M in gross proceedsNEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc....
Daré Bioscience Announces Reverse Stock Split
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) --...
TRxADE Health, Inc. Files its Q1 10-Q; Reporting Positive Net Income Due to Asset Sale
TAMPA, FL, June 27, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (Nasdaq: MEDS) (the “Company”), announced today that with the...
GRI Bio Announces Pricing of $4 Million Public Offering
LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for...
KALA BIO Announces $12,500,000 Private Placement
ARLINGTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research,...
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company...
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted...
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos’ Flagship CARE Oral...
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),...
OraSure Technologies Supports National HIV Testing Day
BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic...
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide...
Expanded Access to XHANCE with Addition to National Commercial Formularies
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose...
Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery
DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced...
Oculis and EURETINA Announces the Ramin Tadayoni Award
ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a...